Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)

Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies.

Announces Earnings Release Date

Carl Hull to Retire as Executive Chairman

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.

Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies.

Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D

SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics.

Cygnus Technologies (Cygnus), TriLink BioTechnologies (TriLink®), both part of Maravai LifeSciences (NASDAQMRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an assay with unparalleled sensitivity and specificity to help produce safer, more stable biotherapeutics that surpass regulatory standards.

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.

Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation

Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth.

TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June.

Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation

TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications.

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

On April 1, 2024 Zacks Small-Cap Research Report was updated highlighting Dyadic International Inc. (NASDAQDYAI) accomplishments to date. Dyadic provided 2023 operational and financial results in a press release on March 28, 2024, filed its Form 10-K with the SEC and held a conference call with investors. Dyadic announced a slate of new, repeat or expanded arrangements with at least seven counterparties since the company’s previous earnings update in November.

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.

Numerous companies merit attention at present due to recent developments. This feature offers a brief overview of five such companies.

Lately, several companies have garnered attention for various reasons, and this article aims to delve into five of them, offering insights into their recent developments.

In the past few days, a number of companies have come on the radar of investors for a range of reasons. This feature would provide you with a closer look into several of those companies a bit more closely.